China pharma firm 3SBIO jumps; co to expand oncology portfolio
07/01/2019 07:04
** Shares of 3SBio Inc 1530.HK rise as much as 10.5 pct
after the biopharmaceutical firm says it plans to broaden its
product portfolio in oncology through collaboration with Samsung
Bioepis Co Ltd
** The Liaoning-based company teams up Samsung Bioepis for
the clinical development and commercialization of multiple
biosimilar candidates developed by Samsung Bioepis in mainland
China, excluding Hong Kong, Macau, Taiwan urn:newsml:reuters.com:*:nFWN1Z6035
** Samsung Bioepis is a joint venture between Samsung
BioLogics 207940.KS and Biogen BIIB.O urn:newsml:reuters.com:*:nS6N1YV02Q
** 3SBio has underperformed the Hang Seng Commerce &
Industry Index sector .HSNC by 17.4 percentage points in the
past one month
** The index .HSNC climbs 1.1 pct on Monday
(Reuters Messaging: donny.kwok.thomsonreuters.com@reuters.net)